Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers
Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Terminated
change in the therapeutic indication
Other terminated trials from Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Leiomyoma · Sep 2021
- Leiomyoma, Uterine · Dec 2019
- Polycystic Ovary Syndrome · Phase PHASE4 · May 2018
- Pneumococcal Meningitis · Phase PHASE4 · Dec 2015
- Blood Loss · Phase PHASE3 · May 2015
See all terminations from Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
This PHASE1 trial investigates Huntington Disease and is currently terminated or withdrawn. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau leads this study, which shows 5 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Palobiofarma SL
For direct contact, visit the study record on ClinicalTrials.gov .